Your browser doesn't support javascript.
loading
The structural and functional investigation of the VapBC43 complex from Mycobacterium tuberculosis.
Eun, Hyun-Jong; Lee, Jooyeon; Kang, Su-Jin; Lee, Bong-Jin.
Afiliación
  • Eun HJ; Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul, 08826, South Korea.
  • Lee J; Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul, 08826, South Korea.
  • Kang SJ; College of Pharmacy, Dongduk Women's University, Seoul, 02748, South Korea.
  • Lee BJ; Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul, 08826, South Korea. Electronic address: lbj@nmr.snu.ac.kr.
Biochem Biophys Res Commun ; 616: 19-25, 2022 08 06.
Article en En | MEDLINE | ID: mdl-35636251
Toxin - Antitoxin systems are crucial for bacterial survival against harsh circumstances such as antibiotic treatment. The VapBC systems are the most abundant Toxin-Antitoxin systems among the Toxin - Antitoxin systems in the Mycobacterium tuberculosis. The VapBC43 system is one of them, which is related to the response to the vancomycin treatment. However, the structure of the VapBC43 complex remained unknown. Here, we present the crystal structure of the VapBC43 complex in which a single VapB43 molecule binds to the VapC43 dimer. The electrophoretic mobility shift assay shows that the VapB43 can bind to its promoter DNA. In addition, this structure reveals that the VapC43 contains a PIN (PilT N-terminus) domain motif which is essential for ribonuclease activity but has less conserved acidic residues than other homologs. The results of ribonuclease assays show that the VapC43 exhibits ribonuclease activity despite the lack of acidic residues which are well conserved in a PIN domain superfamily. Based on the previous finding that the VapBC43 contributes to the survival of Mycobacterium tuberculosis under vancomycin treatment, the structural information of the VapBC43 complex may enable the development of the inhibitor of VapC43 that can be used as an adjuvant for vancomycin therapy against M. tuberculosis.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Toxinas Bacterianas / Antitoxinas / Mycobacterium tuberculosis Tipo de estudio: Prognostic_studies Idioma: En Revista: Biochem Biophys Res Commun Año: 2022 Tipo del documento: Article País de afiliación: Corea del Sur Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Toxinas Bacterianas / Antitoxinas / Mycobacterium tuberculosis Tipo de estudio: Prognostic_studies Idioma: En Revista: Biochem Biophys Res Commun Año: 2022 Tipo del documento: Article País de afiliación: Corea del Sur Pais de publicación: Estados Unidos